Insider Trading Alert - KMB, IBKR And WST Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 26, 2014, 172 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $41.00 to $204,930,000.00.

Highlighted Stocks Traded by Insiders:

Kimberly-Clark Corporation (KMB) - FREE Research Report

Palmer Anthony J. who is Pres Global Brands & Inno at Kimberly-Clark Corporation sold 10,465 shares at $110.67 on Feb. 26, 2014. Following this transaction, the Pres Global Brands & Inno owned 0 shares meaning that the stake was reduced by 100% with the 10,465-share transaction.

The shares most recently traded at $108.42, down $2.25, or 2.08% since the insider transaction. Historical insider transactions for Kimberly-Clark Corporation go as follows:

  • 4-Week # shares sold: 7,003
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 7,003
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 25,231

The average volume for Kimberly-Clark Corporation has been 1.8 million shares per day over the past 30 days. Kimberly-Clark Corporation has a market cap of $41.7 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 5.29% year-to-date as of the close of trading on Wednesday.

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care, consumer tissue, and health care products worldwide. It operates through four segments: Personal Care, Consumer Tissue, K-C Professional, and Health Care. The stock currently has a dividend yield of 3.05%. The company has a P/E ratio of 19.9. Currently there are 2 analysts that rate Kimberly-Clark Corporation a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KMB - FREE

TheStreet Quant Ratings rates Kimberly-Clark Corporation as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Kimberly-Clark Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Interactive Brokers Group (IBKR) - FREE Research Report

Nemser Earl H who is Vice Chairman at Interactive Brokers Group sold 562 shares at $21.85 on Feb. 26, 2014. Following this transaction, the Vice Chairman owned 0 shares meaning that the stake was reduced by 100% with the 562-share transaction.

Brody Paul Jonathan who is Chief Financial Officer at Interactive Brokers Group sold 311 shares at $21.85 on Feb. 26, 2014. Following this transaction, the Chief Financial Officer owned 0 shares meaning that the stake was reduced by 100% with the 311-share transaction.

Galik Milan who is SVP Software Development at Interactive Brokers Group sold 1,800 shares at $22.00 on Feb. 26, 2014. Following this transaction, the SVP Software Development owned 812,117 shares meaning that the stake was reduced by 0.22% with the 1,800-share transaction.

The shares most recently traded at $22.02, up $0.02, or 0.08% since the insider transaction. Historical insider transactions for Interactive Brokers Group go as follows:

  • 4-Week # shares sold: 12,600
  • 12-Week # shares sold: 48,600
  • 24-Week # shares sold: 106,600

The average volume for Interactive Brokers Group has been 575,800 shares per day over the past 30 days. Interactive Brokers Group has a market cap of $1.1 billion and is part of the financial sector and financial services industry. Shares are down 9.12% year-to-date as of the close of trading on Wednesday.

Interactive Brokers Group, Inc. operates as an automated electronic broker and market maker. The stock currently has a dividend yield of 1.78%. The company has a P/E ratio of 26.1. Currently there are 3 analysts that rate Interactive Brokers Group a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IBKR - FREE

TheStreet Quant Ratings rates Interactive Brokers Group as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Interactive Brokers Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

West Pharmaceutical Services (WST) - FREE Research Report

Paproski John E who is President-Delivery Systems at West Pharmaceutical Services sold 8,500 shares at $47.48 on Feb. 26, 2014. Following this transaction, the President-Delivery Systems owned 54,590 shares meaning that the stake was reduced by 13.47% with the 8,500-share transaction.

The shares most recently traded at $46.00, down $1.48, or 3.22% since the insider transaction. Historical insider transactions for West Pharmaceutical Services go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares sold: 60,302

The average volume for West Pharmaceutical Services has been 323,500 shares per day over the past 30 days. West Pharmaceutical Services has a market cap of $3.2 billion and is part of the health care sector and health services industry. Shares are down 5.83% year-to-date as of the close of trading on Wednesday.

West Pharmaceutical Services, Inc. manufactures and sells components and systems for injectable drug delivery and plastic packaging, as well as delivery system components for the pharmaceutical, healthcare, and consumer products industries. The stock currently has a dividend yield of 0.86%. The company has a P/E ratio of 28.5. Currently there is 1 analyst that rates West Pharmaceutical Services a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WST - FREE

TheStreet Quant Ratings rates West Pharmaceutical Services as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full West Pharmaceutical Services Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

Buy Stocks That Are Right for You: Cramer's 'Mad Money' Recap (Friday 2/16/18)

Buy Stocks That Are Right for You: Cramer's 'Mad Money' Recap (Friday 2/16/18)

Lethal Inflationary Pressures Are Lurking, Says World's Biggest Companies

Lethal Inflationary Pressures Are Lurking, Says World's Biggest Companies

What Stock Market Correction?

What Stock Market Correction?

Kimberly-Clark Could Slowly Improve From Here, But There's Still Risk

Kimberly-Clark Could Slowly Improve From Here, But There's Still Risk

Jim Cramer: Boxes Being Checked, Bulls Being Rewarded

Jim Cramer: Boxes Being Checked, Bulls Being Rewarded